Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBX 4291
- Development stage
- Phase 1
- Lead developer
- MBX Biosciences
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
MBX 4291 is an investigational long-acting peptide prodrug that acts as a dual agonist of the glucagon-like peptide 1 receptor (GLP‑1R) and gastric inhibitory polypeptide receptor (GIPR). It is being developed by MBX Biosciences for the treatment of obesity. Designed using the company’s proprietary Precision Endocrine Peptide (PEP™) platform, it aims to provide once-monthly dosing, improved gastrointestinal tolerability, and increased maximal weight loss compared to existing therapies. In preclinical studies, its active component demonstrated similar activity and body weight loss as tirzepatide but with a longer duration of action, supporting potential for less frequent administration[1][2][5][6].
- Other names
- GLP-l/GIP agonist (MBX Biosciences)GLP1xGIP co agonistGLP-1xGIP co agonistGLP 1xGIP co agonist
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on MBX 4291.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBX 4291.